Omics Core
Nov 2019
240d
Nanthealth, Inc.
1
Total
1
Cleared
0
Denied
Nanthealth, Inc. — FDA 510(k) Submissions
Nanthealth, Inc. has submitted 1 FDA 510(k) premarket notifications since 2019, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include Next Generation Sequencing Based Tumor Profiling Test . Use the specialty filter in the sidebar to narrow results.
1 devices